top of page
Treprostinil benefits PAH patients with cardiovascular issues
Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new...
PHA Canada
Feb 41 min read
Â
Â
Â
Op-ed: Speed up patient access to life-saving medications
"Imagine being told that a new treatment exists — one that could save your life or significantly improve it — but that you’ll have to...
PHA Canada
Jan 281 min read
Â
Â
Â


Patient Voice: Angel's Story
Angel Ouellet One day when I was six years old, I saw a favourite teacher at the end of the corridor at school and ran to give them a...
Patient Voice
Jan 162 min read
Â
Â
Â


Patient Voice: Rose's Story
Rose Jardim When I was 50 years old, I cut myself while shaving my legs. And then the cut just didn’t heal. It developed into a deep...
Patient Voice
Jan 162 min read
Â
Â
Â


Patient Voice: Tarya's Story
Tarya Morel Looking back, I’ve had difficulties with shortness of breath for as long as I can remember, but it never really occurred to...
Patient Voice
Jan 162 min read
Â
Â
Â
Sotatercept safe and effective across cardiac index groups
Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size...
PHA Canada
Dec 18, 20241 min read
Â
Â
Â
Take Action to Support Canadian Charities
The holiday season is the most critical fundraising period for charities, with many relying on year-end donations to sustain their work....
PHA Canada
Dec 17, 20241 min read
Â
Â
Â
A Simple Step to Save Lives: Ontario's Tax Return Initiative for Organ Donation
In an innovative new collaboration between Trillium Gift of Life Network (TGLN) and the provincial and federal governments, millions of...
PHA Canada
Dec 10, 20241 min read
Â
Â
Â
Pulmonary Hypertension Association of Canada Urges Québec's Minister of Health to Join pCPA Negotiations for Sotatercept
INESSS recognizes sotatercept's therapeutic value but recommends against public funding Vancouver BC (5 December 2024) -- The Pulmonary...
PHA Canada
Dec 6, 20242 min read
Â
Â
Â
Improved reimbursements for PH patients in Northern Ontario
As of December 1, the Ontario government has improved reimbursement amounts for people in Northern Ontario who need to travel for...
PHA Canada
Dec 4, 20241 min read
Â
Â
Â
ZENITH study shows sotatercept is effective for PAH patients at high risk of mortality
The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...
PHA Canada
Nov 26, 20241 min read
Â
Â
Â
Pulmonary Hypertension Association of Canada Applauds Canada’s Drug Agency Recommendation for Public Funding of Winrevair™ (sotatercept)
Date: November 7, 2024 Location: Vancouver, BC Â The Pulmonary Hypertension Association of Canada (PHA Canada) is thrilled to announce...
PHA Canada
Nov 6, 20243 min read
Â
Â
Â


Mental health in PAH
A webinar hosted by the Pulmonary Hypertension Knowledge Sharing Platform this week talked about a couple of studies on mental health in...
PHA Canada
Oct 31, 20241 min read
Â
Â
Â


Interview with Liss Cairns from Plan Institute - RDSP Awareness Month
💜 RDSP Awareness Month is almost over , but it’s not too late to learn about the benefits of a Registered Disability Savings Plan (RDSP)...
PHA Canada
Oct 28, 20241 min read
Â
Â
Â
Update: Canadian Drug Agency Funding Success for Pulmonary Hypertension Research
Great news for the Pulmonary Hypertension (PH) community! Through the Canadian Drug Agency's (CDA) funding initiative for rare diseases,...
PHA Canada
Oct 24, 20241 min read
Â
Â
Â
Rural and urban PH patients receive equivalent care
As most PH clinics are in large cities, PH patients living in rural or remote areas and who must travel long distances to their clinic...
PHA Canada
Oct 24, 20241 min read
Â
Â
Â
PHA Canada Advocates for Fair Access: September Submission to PMPRB
PHA Canada is proud to announce our latest submission to the Patented Medicines Pricing Review Board (PMPRB) Â this September. As the...
PHA Canada
Sep 11, 20241 min read
Â
Â
Â
Sotatercept (WINREVAIR®) Authorized in Canada for PAH Treatment
Merck has announced that WINREVAIR® (sotatercept) is now authorized for use in Canada in combination with standard pulmonary arterial...
PHA Canada
Sep 5, 20241 min read
Â
Â
Â


Traveling with PH: Angele's Family Adventures Across Canada - Blog 4/6
Blog 4/6 - Getting there Guillaume and I love road-tripping! Ever since we met in 2001, we have frequently hit the road in search of...
Angèle Belliveau, Patient
Jul 22, 20244 min read
Â
Â
Â


Uncovering Major Inequities in PH Care Across Canada
A new investigation, "A Canadian Initiative: Exploring Adult Pulmonary Hypertension," highlights critical issues such as diagnostic...
PHA Canada
Jul 22, 20241 min read
Â
Â
Â
bottom of page
